company background image
LDX

Lumos Diagnostics HoldingsASX:LDX Stock Report

Market Cap

AU$141.1m

7D

3.3%

1Y

n/a

Updated

18 Oct, 2021

Data

Company Financials +
LDX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LDX Overview

Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests.

Price History & Performance

Summary of all time highs, changes and price drops for Lumos Diagnostics Holdings
Historical stock prices
Current Share PriceAU$0.94
52 Week HighAU$0.82
52 Week LowAU$1.50
Beta0
1 Month Change-13.36%
3 Month Change-24.50%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.24%

Recent News & Updates

Shareholder Returns

LDXAU Medical EquipmentAU Market
7D3.3%1.6%1.7%
1Yn/a-8.5%20.3%

Return vs Industry: Insufficient data to determine how LDX performed against the Australian Medical Equipment industry.

Return vs Market: Insufficient data to determine how LDX performed against the Australian Market.

Price Volatility

Is LDX's price volatile compared to industry and market?
LDX volatility
LDX Beta0
Industry Beta0.57
Market Beta1

Stable Share Price: LDX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: Insufficient data to determine LDX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aRob Samburskyhttps://lumosdiagnostics.com

Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; ViraDx, a combined COVID/Influenza test for acute respiratory infections; and CoviDx, an antigen test for COVID-19.

Lumos Diagnostics Holdings Fundamentals Summary

How do Lumos Diagnostics Holdings's earnings and revenue compare to its market cap?
LDX fundamental statistics
Market CapAU$141.14m
Earnings (TTM)-AU$20.13m
Revenue (TTM)AU$25.06m

5.6x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LDX income statement (TTM)
RevenueAU$25.06m
Cost of RevenueAU$13.53m
Gross ProfitAU$11.52m
ExpensesAU$31.65m
Earnings-AU$20.13m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin45.99%
Net Profit Margin-80.33%
Debt/Equity Ratio0%

How did LDX perform over the long term?

See historical performance and comparison

Valuation

Is Lumos Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?

1.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: LDX (A$0.94) is trading above our estimate of fair value (A$0.06)

Significantly Below Fair Value: LDX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: LDX is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: LDX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LDX is good value based on its PB Ratio (1.8x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Lumos Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

36.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LDX's revenue (21.6% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: LDX's revenue (21.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LDX is forecast to be unprofitable in 3 years.


Past Performance

How has Lumos Diagnostics Holdings performed over the past 5 years?

-49.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: LDX is currently unprofitable.

Growing Profit Margin: LDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LDX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: LDX has a negative Return on Equity (-25.89%), as it is currently unprofitable.


Financial Health

How is Lumos Diagnostics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: LDX's short term assets (A$76.1M) exceed its short term liabilities (A$43.2M).

Long Term Liabilities: LDX's short term assets (A$76.1M) exceed its long term liabilities (A$9.6M).


Debt to Equity History and Analysis

Debt Level: LDX is debt free.

Reducing Debt: LDX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LDX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 45.1% each year


Dividend

What is Lumos Diagnostics Holdings's current dividend yield, its reliability and sustainability?

0.27%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LDX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Rob Sambursky

no data

Tenure

AU$976,592

Compensation

Dr. Robert P. Sambursky, M.D., also known as Rob, co-founded Rapid Pathogen Screening Inc. in 2004 and serves as its Executive Chairman, Chief Executive Officer, President and Chief Medical Officer. Dr. Sa...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD724.85K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Insufficient data to compare Rob's compensation with company performance.


Leadership Team

Experienced Management: LDX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: LDX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: LDX only recently listed within the past 12 months.


Top Shareholders

Company Information

Lumos Diagnostics Holdings Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Lumos Diagnostics Holdings Limited
  • Ticker: LDX
  • Exchange: ASX
  • Founded: 2004
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$141.143m
  • Shares outstanding: 150.15m
  • Website: https://lumosdiagnostics.com

Location

  • Lumos Diagnostics Holdings Limited
  • Level 4
  • 96-100 Albert Road
  • Melbourne
  • Victoria
  • 3205
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:39
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.